Supporting Alzheimer’s Disease Diagnosis with Artificial Intelligence
MINT-AD
Multimodal Interpretable Transformer for Alzheimer's Disease.
Empower Clinical Excellence
MINT-AD leverages decades of international research in genomics, clinical practice, and cognitive science into a clinical decision support tool.
Brings world-class AI risk prediction and decision support directly into the hands of:
• Physicians:
Timely insights for underserved communities without complex infrastructure.
• Researchers:
Multimodal data analysis to unlock new risk factors and understand disease progression.
Data Integration & Purpose
A comprehensive data integration allows MINT-AD to identify subtle changes and detect early patterns of cognitive decline.
Cognitive tests
Cognitive tests
Neuropsychological evaluations, memory, & language attention,Listens, Technology That Cares
Omics Data
Omics Data
Genetics, specific, Biomarkers, epigenetics
Brain images
Brain Images
Magnetic Resonance Imaging (MRI), Computed Tomography scans, & PET
Clinical History
Clinical History
Family history, over 390 medical variables
Demographic
Demographic
Location, age, gender, living conditions and other socioeconomic conditions
Why develop
MINT-AD
Reduces diagnostic delays in underserved areas with limited equipment.
Supports identification of at-risk patients and helps inform public health policy.
Reveals socio-economic and lifestyle combinations that impact Alzheimer’s progression.
Empowering Better Outcomes Through
Data-Driven Alzheimer’s Solutions
Evidence You Can Trust:
Interpretable, science-backed outputs with clarity around uncertainty.
Informed Recommendations, Personalized Outcomes:
Timely insights for underserved communities without complex infrastructure.
Seamless Integration for Deeper Discovery:
Multidimensional data reveals novel combinations of social, genetic, and lifestyle determinants.
Reduce inequality:
Designed for high accuracy, particularly in scenarios where false negatives are common.
Meet the leader behind MINT-AD
Other projects you may like
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
